
|Articles|November 1, 2003
A Matter of Preference
Amsterdam, The Netherlands - Methotrexate and cyclosporine do not differ significantly in efficacy as systemic therapies for moderate to severe chronic plaque psoriasis, according to Menno de Rie, M.D., Ph.D., associate professor of dermatology at the University of Amsterdam. Dr. de Rie and colleagues compared the two therapies in a randomized study of 88 patients with moderate to severe psoriasis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5














